Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — HCW Annual Global Investment Conference 2025
33 slides from Nykode Therapeutics Asa's conference presentation, Sep 10, 2025
Slide 1: HCW Annual Global Investment Conference
HCW Annual Global Investment Conference New York | September 10, 2025
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Nykode Therapeutics: Overview
Nykode Therapeutics: Overview Abi-Suva (VB10.16): addressing markets with blockbuster potential • High conviction from 3 trials across indications showing strong and durable clinical response correlated with antigen specific immune responses • Phase 2 RCT in 1L r/m head and neck cancer to deliver me
Slide 4: Engaging Antigen Presenting Cells to direct precise immune responses
Engaging Antigen Presenting Cells to direct precise immune responses APC’s and their importance How does Nykode use APCs • Antigen Precenting Cells process and • Proprietary APC-targeting technology present antigens to T-cells to develop differentiated assets tailor- made for oncology and autoimmune
Slide 5: Modular immunotherapy technology allows APC-targeting to direct precise immune responses
Modular immunotherapy technology allows APC-targeting to direct precise immune responses DNA plasmid Targeting unit to attract and bind APCs encoding Exchangeable in order to induce different immune response profiles to specific Nykode immunotherapy diseases1 Dimerization unit for crosslinking targe
Slide 6: Focused execution on oncology and autoimmune diseases – significant untapped potential remains
Focused execution on oncology and autoimmune diseases – significant untapped potential remains What Nykode’s proprietary APC targeting technology How it works Enhancing the immune system Reduces immune functions through APCs to activate through APCs to activate T-Cells (both CD8 and CD4) Treg cells
Slide 7: Abi-suva in HPV16+ cancers
Abi-suva in HPV16+ cancers Nykode Therapeutics | HCW Conference | Non-Confidential 7
Slide 8: Abi-suva has potential to fulfill significant unmet need in 1L R/M HNSCC
Abipapogene Suvaplasmid (abi-suva) has potential to fulfill significant unmet need in 1L R/M HNSCC Incidences Treatment Forecasted HPV+ HNSCC sales*** Annual estimated incidence of ~105,000 19% ORR and 12.3 mOS for Estimated 7MM market (bn$) HPV16+ cancer in US and EU: Current SOC in 1L R/M HNSCC Le
Slide 9: Abi-suva has potential to fulfill significant unmet need
Abi-suva has potential to fulfill significant unmet need Achievements Opportunity - HNSCC Path forward KOLs seek more specific HPV+ Initiating Abili-T trial Positive data in 100 patients Phase 2 randomized across 3 indications treatment options in HNSCC. controlled trial enrolling up to 100 patients
Slide 10: Nykode is well positioned in the field of HPV16 positive 1L R/M HNSCC
Nykode is well positioned in the field of HPV16 positive 1L R/M HNSCC Approval of Bi-specific Therapeutic Keytruda antibodies, HPV vaccines in neo/adjuvant targeting EGFR LA HNSCC Targeting predominantly Two main competitors with ongoing Relevant predominantly the distinct HPV negative randomized cl
Slide 11: Two completed and one ongoing clinical trial, with randomized Phase 2 close to being initiated
Two completed and one ongoing clinical trial, with randomized Phase 2 close to being initiated Completed and ongoing: Number of Trial Phase Study Design Indication patients Treatment Status Open-label, HPV16-induced high-grade cervical intraepithelial Abi-Suva (3mg) Completed (data C-01 Phase 1/2a 3
Slide 12: Strong clinical effect in 2L+ cervical cancer
Strong clinical effect in 2L+ cervical cancer Overall response rate (ORR) indicates a strong Significant increase in overall response rate clinical effect with abi-suva + atezolizumab (ORR) compared to CPI monotherapy Overall response in PD-L1+ (n = 24) ORR compared to CPI monotherapy: 100% 90% 29%
Slide 13: Strong overall survival in 2L+ cervical cancer
Strong overall survival in 2L+ cervical cancer Overall survival of 24.7 mos in PD-L1+ patients Overall survival is longer than CPI monotherapy treated with abi-suva + atezolizumab for 12 historic controls months mOS compared to SOC 24,7 ~109% 13,9 10,6 11,0 24,7 13,9 10,6 11,0 Abi-suva + Atezo Pembr
Slide 14: Strong monotherapy activity observed in HSIL patients
Strong monotherapy activity observed in HSIL patients Patients showed consistent reduction in lesion size and regression of lesion severeness • Strong monotherapy efficacy observed in premalignant cervical lesions (CIN2/3, HSIL patients) • Safe and well tolerated Nykode Therapeutics | HCW Conference
Slide 15: Immune responses are significantly correlated with clinical effect across trials
Immune responses are significantly correlated with clinical effect across trials C-02 2L+cervical cancer in C-01 HSIL patients monotherapy combination with atezolizumab 1500 1000 • Significant correlation between p=0.0113 500 250 HPV16-specific T cell responses and clinically SFU/106 PBMC 200 releva
Slide 16: Ongoing C-03 trial in 1L R/M HNSCC has safety cleared all doses
Ongoing C-03 trial in 1L R/M HNSCC has safety cleared all doses Key inclusion Treatment Objective criterion • HPV16+ r/m HNSCC Abipapogene Abipapogene Abipapogene • PD-L1+ suvaplasmid + suvaplasmid + suvaplasmid + Select RP2D • Measurable disease pembrolizumab 3mg pembrolizumab 6mg pembrolizumab 9mg
Slide 17: Initiating Abili-T, randomized controlled trial enrolling up to 100 1L HNSCC patients
Initiating Abili-T, randomized controlled trial enrolling up to 100 1L HNSCC patients Key inclusion Treatment Endpoints criterion ORR • HPV16+ r/m HNSCC Abipapogene suvaplasmid + pembrolizumab DOR RMDOR • PD-L1+ DCR R • Measurable disease PFS (1:1) • ECOG PS 0-1 OS • GRIm 0-1 TEAEs Pembrolizumab Imm
Slide 18: Abili-T designed to provide Proof of Concept for Abi-suva
First data from C-03 1H2026 Abili-T designed to provide Proof of Concept for Abi-suva with potential spill-over Well positioned in the field of HPV+ validation across HPV16 1L R/M HNSCC segment and for Nykode technology platform including RCT with ~100 patients with INT meaningful interim readout wi
Slide 19: VB10.NEO Individualized NeoAntigen Therapy
VB10.NEO Individualized NeoAntigen Therapy Nykode Therapeutics | HCW Conference | Non-Confidential 19
Slide 20: Individualized neoantigen therapies (INT) entering defining period
Individualized neoantigen therapies (INT) entering defining period Nykode well-positioned as most attractive unencumbered INT 10 Ongoing peer Ph2 and Potential to treat Ph3 clinical trials. Strong all tumor types focus on adjuvant settings Emerging space Expected key Large potential market and few H
Slide 21: VB10.NEO is well positioned to be the most attractive unencumbered asset
VB10.NEO is well positioned to be the most attractive unencumbered asset Key success factors for an Individualized Neoantigen Therapy: Clinical Antigen selection Supply chain Costs experience Strong immune Proprietary Proven robust Competitive COGS responses across algorithm to select supply chain w
Slide 22: Strong immune responses across basket trials with heavily pre-treated patients
Strong immune responses across 2 basket trials with heavily pre-treated patients N-01 and N-02 both show vaccine induce immune response N-01 100 Strong vaccine-induced immune responses, N-02 85 85 88 even in heavily pre-treated late-stage patients after few vaccinations* 58 45 Persistent expansion o
Slide 23: Clinically validated proprietary Neoantigen selection method
Clinically validated proprietary Neoantigen selection method trained and optimized for Nykode technology Clear correlation between prioritized neoantigens by NeoSELECT and their proven immunogenicity in patients The proprietary AI-driven platform, NeoSELECT systematically prioritizes the most immuno
Slide 24: VB10.NEO has a proven robust supply chain with a significant competitive cost advantage
VB10.NEO has a proven robust supply chain with a significant competitive cost advantage INTs require a highly complex supply chain Nykode has an established and robust supply chain Turn-Around-Time (weeks) 8. Clinical site 7. Storage 1. Biopsy and supply assessment 2. Sequencing of 18 6. GMP filling
Slide 25: VB10.NEO is well positioned in the field of individualized neoantigen therapies
Peer readouts within next 18 months can create a strong conviction for INTs VB10.NEO is well positioned VB10.NEO meets requirement for in the field of individualized ideal INT technology neoantigen therapies. Continuing to strengthen this position with key activities focused on further optimizing ro
Slide 26: Antigen-Specific Immune Tolerance
Antigen-Specific Immune Tolerance Nykode Therapeutics | HCW Conference | Non-Confidential 26
Slide 27: A new way of thinking about autoimmune disease treatment
A new way of thinking about autoimmune disease treatment The Problem The Future Current treatment focus on symptom management -- do not address the underlying root cause of disease . Unsolved Side effects frequently impairing the quality of life of patients Antigen-Specific Immune Tolerance is a new
Slide 28: Nykode's ASIT platform shows Best-In-Class potential
Nykode’s ASIT platform shows Best-In-Class potential 4 Targeted vaccine 2 PBS ✱✱ EAE score (0-8) 200 3 160 AUC (5-35) Long durable reversion of disease symptoms 2 120 80 1 40 0 0 PBS Targeted 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 vaccine Days post EAE indu
Slide 29: Nykode's ASIT platform impacts all major arms of the immune system
Nykode’s ASIT platform impacts all major arms of the immune system Increase Reduce auto- Reduce regulatory antibodies Day 12 post EAE induction: effector T cells MOG-recall Splenocytes T cells anti-MOG (35-55) IgG Foxp3+ Treg cells ✱✱✱ Th1.17 cells IFN-γ Lag3 Day 7 % Foxp3+ of CD4+Thy1.2+ cells 30 ✱
Slide 30: Nykode aspire to built best in class ASIT platform
New paradigm with untapped market. Additional upside in allergy and organ transplant rejection Nykode aspire to built Nykode’s ASIT technology shown important progress with durable best in class ASIT effect and precise modulation of all platform key elements of the immune system Increasing investmen
Slide 31: Outlook
Outlook Nykode Therapeutics | HCW Conference | Non-Confidential 31
Slide 32: Well-positioned to execute strategy and meet inflection points
Well-positioned to execute strategy and meet inflection points Cash Runway Next 6-12 Months Next 12-24 Months Cash runway into 2028-2029* C-03 Efficacy data (1H26) Abili-T first interim analysis (2027) Sufficient to meet significant C-03 Durability data (2H26) inflection points Key peer readouts on
Slide 33: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations IR@nykode.com Nykode Therapeutics | HCW Conference | Non-Confidential
Nykode Therapeutics — HCW Annual Global Investment Conference 2025 on 6ix